InsiderTrades.com logo
Elon to Transform U.S. Economy?
From Porter & Company   |   Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.

DNTH Insider Trading

Insider Ownership Percentage: 16.56%
Insider Buying (Last 12 Months): $1,314,676.05
Insider Selling (Last 12 Months): $0.00

Dianthus Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Dianthus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dianthus Therapeutics Share Price & Price History

Current Price: $28.97
Price Change: ▲ Price Increase of +0.88 (3.13%)
As of 07/26/2024 01:00 AM ET

This chart shows the closing price history over time for DNTH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
From Paradigm Press   |   Ad
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Click here to see it because it’s a SHOCKER…

Dianthus Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/29/2023Fairmount Funds Management LlcDirectorBuy24,670$13.63$336,252.101,928,503View SEC Filing Icon  
9/26/2023Fairmount Funds Management LlcDirectorBuy30,000$13.15$394,500.001,903,833View SEC Filing Icon  
9/21/2023Simrat RandhawaInsiderBuy2,000$13.20$26,400.002,000View SEC Filing Icon  
9/19/2023Fairmount Funds Management LlcDirectorBuy30,000$13.20$396,000.001,873,833View SEC Filing Icon  
9/12/2023Fairmount Funds Management LlcDirectorBuy14,887$10.85$161,523.951,834,466View SEC Filing Icon  
See Full Table
Nvidia’s Quiet $1 Trillion Pivot
From Weiss Ratings   |   Ad
Nvidia recently added $277 billion in market cap … IN ONE DAY.
Find out details on these three critical Nvidia partners immediately.

SEC Filings (Institutional Ownership Changes) for Dianthus Therapeutics (NASDAQ:DNTH)

47.53% of Dianthus Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DNTH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Dianthus Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
7/26/2024Bank of New York Mellon Corp80,935$2.10M0.0%+860.5%0.276%Search for SEC Filing on Google Icon
7/12/2024SG Americas Securities LLC4,333$0.11M0.0%N/A0.015%Search for SEC Filing on Google Icon
5/20/2024Virtu Financial LLC12,995$0.39M0.0%N/A0.044%Search for SEC Filing on Google Icon
5/17/2024RA Capital Management L.P.2,333,000$69.99M0.9%N/A7.949%Search for SEC Filing on Google Icon
5/16/2024Janus Henderson Group PLC375,044$11.25M0.0%N/A1.278%Search for SEC Filing on Google Icon
5/16/2024Bain Capital Life Sciences Investors LLC2,992,028$89.76M7.2%N/A10.194%Search for SEC Filing on Google Icon
5/14/2024StemPoint Capital LP43,456$1.30M0.3%N/A0.148%Search for SEC Filing on Google Icon
5/10/2024Acadian Asset Management LLC4,012$0.12M0.0%-77.6%0.014%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.537,828$16.14M0.0%+250.0%1.833%Search for SEC Filing on Google Icon
5/6/2024Atlas Venture Life Science Advisors LLC186,979$5.61M0.5%-21.1%0.637%Search for SEC Filing on Google Icon
5/2/2024Hussman Strategic Advisors Inc.21,000$0.63M0.1%N/A0.072%Search for SEC Filing on Google Icon
2/15/2024Octagon Capital Advisors LP554,000$5.76M0.9%+15.4%3.738%Search for SEC Filing on Google Icon
2/14/2024Vestal Point Capital LP135,000$1.40M0.1%N/A0.911%Search for SEC Filing on Google Icon
2/13/2024Tower Research Capital LLC TRC 2,430$25K0.0%N/A0.016%Search for SEC Filing on Google Icon
12/6/2023Citigroup Inc.3,868$53K0.0%N/A0.026%Search for SEC Filing on Google Icon
11/15/2023Laurion Capital Management LP36,393$0.50M0.0%N/A0.960%Search for SEC Filing on Google Icon
11/14/2023Avidity Partners Management LP1,217,554$16.64M0.7%N/A32.125%Search for SEC Filing on Google Icon
11/13/2023Atlas Venture Life Science Advisors LLC236,979$3.24M0.5%N/A6.249%Search for SEC Filing on Google Icon
11/13/2023Acadian Asset Management LLC22,299$0.30M0.0%N/A0.588%Search for SEC Filing on Google Icon
11/13/2023FMR LLC2,218,212$28.96M0.0%N/A58.497%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Dianthus Therapeutics logo
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Read More on Dianthus Therapeutics

Today's Range

Now: $28.97
Low: $28.88
High: $31.61

50 Day Range

MA: $25.27
Low: $20.13
High: $29.00

52 Week Range

Now: $28.97
Low: $6.58
High: $33.77

Volume

237,145 shs

Average Volume

190,033 shs

Market Capitalization

$850.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Who are the company insiders with the largest holdings of Dianthus Therapeutics?

Dianthus Therapeutics' top insider investors include:
  1. Fairmount Funds Management Llc (Director)
  2. Simrat Randhawa (Insider)
Learn More about top insider investors at Dianthus Therapeutics.

Who are the major institutional investors of Dianthus Therapeutics?

Dianthus Therapeutics' top institutional shareholders include:
  1. Bank of New York Mellon Corp — 0.28%
  2. SG Americas Securities LLC — 0.01%
Learn More about top institutional investors of Dianthus Therapeutics stock.

Which institutional investors are buying Dianthus Therapeutics stock?

Within the last quarter, DNTH stock was purchased by institutional investors including:
  1. Bank of New York Mellon Corp
  2. SG Americas Securities LLC
During the previous year, these company insiders have bought Dianthus Therapeutics stock:
  1. Fairmount Funds Management Llc (Director)
  2. Simrat Randhawa (Insider)
Learn More investors buying Dianthus Therapeutics stock.
Elon to Transform U.S. Economy?
From Porter & Company   |   Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.